Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05684978 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus
A Phase 4 study, sponsored by Wayne State University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT05684978 is a Phase 4 study that was terminated before completion, run by Wayne State University. The registered enrollment target is 1 participants.
The verdict
NCT05684978, a Phase 4 study, was terminated before completion, sponsored by Wayne State University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This project is aiming to better understand the use of perampanel as an appropriate standard-of-care therapy for treatment refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety. The study will recruit 25 patients at WSU. The study will last for about 96 weeks and will involve a screening visit and two in clinic visits at 3 and 6 months. If the subjects give written informed consent and meet all eligibility criteria they will be clinically evaluated and will be given the study drug. This study will involve recording of patients medical history, drug history and epilepsy history. A physical exam and a and neurological exam will also be performed to study the heath status of the participant. Results and patient information will be stored in a database for analysis to find commonality among key factors that have been seen in past research.
Interventions
- DRUG Perampanel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-10-10 |
| Est. Completion | 2025-10-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05684978
The ClinicalTrials.gov registry entry for NCT05684978 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wayne State University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Perampanel is the first listed.
NCT05684978 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05684978 about?
NCT05684978 is a clinical study titled "Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus". This project is aiming to better understand the use of perampanel as an appropriate standard-of-care therapy for treatment refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety. The study will recruit 25 patients at WSU. The study will last for about 96 week...
What is the current status of trial NCT05684978?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2025-10-10. Estimated completion is 2025-10-10.
What interventions are being tested in trial NCT05684978?
The interventions under investigation include: Perampanel (DRUG).
Who is sponsoring clinical trial NCT05684978?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.